Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herman F Staats

Showing results (21-30 of 78) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|October 16, 2018
Adjuvanted Immunotherapy Approaches for Peanut AllergyBrandi T Johnson-Weaver, Herman F Staats, A Wesley Burks, et al.
Clinical and Experimental Vaccine Research|July 31, 2025
Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunityAlison Hofmann Church, Soman N Abraham, Herman F Staats, et al.
Scientific Reports|June 5, 2014
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunityKyle K L Phua, Herman F Staats, Kam W Leong, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 19, 2017
Assessing the satisfaction and burden within an academic animal care and use programJohn N Norton, Randall P Reynolds, Cliburn Chan, et al.
Journal of Pharmaceutical Sciences|September 10, 2011
Stable dry powder formulation for nasal delivery of anthrax vaccineSheena H Wang, Shaun M Kirwan, Soman N Abraham, et al.
Journal of Virology|December 26, 2001
Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunizationCurtis P Bradney, Gregory D Sempowski, Hua-Xin Liao, et al.
Journal of Immunological Methods|November 20, 2008
Identification of recombinant antibodies against multiple distinct toll-like receptors by homolog mining a single immune scFv phage libraryYu-Hsun Chen, Barbara D Lipes, Daniel J Kenan, et al.
Vaccine|May 26, 2009
The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigenAfton L McGowen, Laura P Hale, Christopher P Shelburne, et al.
Vaccine|April 6, 2004
Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissuesUdi Qimron, Lada Paul, Erez Bar-Haim, et al.
Microbiology and Immunology|February 22, 2005
Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirusIndulekha N Gopal, Anita Quinn, Stanley C Henry, et al.
Pageof 8

Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|October 16, 2018
Adjuvanted Immunotherapy Approaches for Peanut AllergyBrandi T Johnson-Weaver, Herman F Staats, A Wesley Burks, et al.
Clinical and Experimental Vaccine Research|July 31, 2025
Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunityAlison Hofmann Church, Soman N Abraham, Herman F Staats, et al.
Scientific Reports|June 5, 2014
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunityKyle K L Phua, Herman F Staats, Kam W Leong, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 19, 2017
Assessing the satisfaction and burden within an academic animal care and use programJohn N Norton, Randall P Reynolds, Cliburn Chan, et al.
Journal of Pharmaceutical Sciences|September 10, 2011
Stable dry powder formulation for nasal delivery of anthrax vaccineSheena H Wang, Shaun M Kirwan, Soman N Abraham, et al.
Journal of Virology|December 26, 2001
Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunizationCurtis P Bradney, Gregory D Sempowski, Hua-Xin Liao, et al.
Journal of Immunological Methods|November 20, 2008
Identification of recombinant antibodies against multiple distinct toll-like receptors by homolog mining a single immune scFv phage libraryYu-Hsun Chen, Barbara D Lipes, Daniel J Kenan, et al.
Vaccine|May 26, 2009
The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigenAfton L McGowen, Laura P Hale, Christopher P Shelburne, et al.
Vaccine|April 6, 2004
Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissuesUdi Qimron, Lada Paul, Erez Bar-Haim, et al.
Microbiology and Immunology|February 22, 2005
Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirusIndulekha N Gopal, Anita Quinn, Stanley C Henry, et al.
Pageof 8